This company has been marked as potentially delisted and may not be actively trading. Range Cancer Therapeutics ETF Rating Add Compare Share Share Ratings Stock AnalysisHoldingsRatingsShort InterestTrendsBuy This Stock Range Cancer Therapeutics ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CNCR Aggregate RatingModerate Buy 2.80Holdings in CNCR have an aggregate rating of Moderate Buy based on 501 analyst ratings issued in the past year covering 50 companies (78.7% of the portfolio).CNCR Aggregate Price Target$10.25High Prediction$10.25Average Prediction$10.25Low Prediction$10.25Holdings in CNCR have an aggregate price target of $10.25 and a range of $10.25 to $10.25 covering 50 companies (78.7% of the portfolio).CNCR Consensus Ratings of HoldingsStrong Buy1 Strong Buy rating(s)Buy21 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Range Cancer Therapeutics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 CNCR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.72%SMMTSummit Therapeutics$27.90+13.1%2.6872 of 5 stars3.00$37.40 34.1%10Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap Up2.27%FATEFate Therapeutics$1.31+5.6%3.745 of 5 stars2.22$5.43 314.4%9Upcoming EarningsNews CoveragePositive News1.87%BNTXBioNTech$104.94+2.5%2.5975 of 5 stars2.89$143.44 36.7%18Upcoming EarningsPositive News1.77%SDGRSchrödinger$25.29+1.6%2.5096 of 5 stars3.00$32.80 29.7%6Upcoming EarningsPositive NewsGap Up1.72%ARVNArvinas$7.72+6.8%3.3926 of 5 stars2.63$25.82 234.5%19Earnings ReportAnalyst ForecastShort Interest ↑News CoverageHigh Trading Volume1.68%FHTXFoghorn Therapeutics$4.24+1.9%2.284 of 5 stars3.00$12.13 186.0%8Upcoming EarningsAnalyst ForecastNews Coverage1.66%TSVT2seventy bio$5.00+0.4%1.7599 of 5 stars2.29$5.60 12.0%7Short Interest ↑News Coverage1.65%JANXJanux Therapeutics$32.88+2.6%3.0574 of 5 stars3.09$95.25 189.7%11Upcoming EarningsInsider TradeNews CoveragePositive News1.65%HCMHUTCHMED$15.00+1.4%1.9739 of 5 stars2.00$19.00 26.7%1Upcoming EarningsShort Interest ↑Gap Up1.64%EXELExelixis$39.60+1.8%4.0044 of 5 stars2.47$37.59 -5.1%19Short Interest ↑Analyst RevisionPositive News1.64%SNDXSyndax Pharmaceuticals$13.73-0.7%3.6671 of 5 stars2.90$36.20 163.7%10Upcoming EarningsNews CoveragePositive News1.64%NUVBNuvation Bio$2.46+8.4%3.4971 of 5 stars3.17$7.83 218.4%6News CoveragePositive NewsHigh Trading Volume1.63%ZYMEZymeworks$12.96+0.6%2.7758 of 5 stars2.88$21.00 62.0%8Upcoming EarningsAnalyst RevisionNews CoveragePositive News1.63%IMCRImmunocore$30.46+1.0%3.2335 of 5 stars2.45$59.44 95.2%11Upcoming EarningsPositive News1.62%IDYAIDEAYA Biosciences$20.93+2.2%3.726 of 5 stars2.93$53.58 156.0%15Upcoming EarningsPositive News1.61%DNAGinkgo Bioworks$7.04+1.1%0.684 of 5 stars1.60$4.58 -35.0%5Upcoming EarningsNews CoverageGap Up1.60%ITOSiTeos Therapeutics$7.77+3.6%2.0538 of 5 stars3.00$25.50 228.2%4Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage1.60%IPHAInnate Pharma$2.26+2.3%2.6124 of 5 stars3.50$11.00 386.7%21.60%ERASErasca$1.58+6.0%2.9822 of 5 stars3.00$4.83 205.9%6Analyst ForecastNews Coverage1.59%GMABGenmab A/S$21.48+2.6%4.4648 of 5 stars2.69$39.17 82.3%13Upcoming EarningsPositive News1.59%STROSutro Biopharma$1.10+2.8%4.3204 of 5 stars2.22$6.63 502.3%9Analyst ForecastNews CoverageGap Down1.58%RVMDRevolution Medicines$40.72+0.2%3.7623 of 5 stars3.00$66.67 63.7%12Upcoming EarningsPositive News1.55%NUVLNuvalent$77.46+1.6%1.7295 of 5 stars2.90$115.50 49.1%10Upcoming EarningsNews Coverage1.54%TYRATyra Biosciences$10.86+3.6%1.8574 of 5 stars3.00$30.83 183.9%6Upcoming EarningsNews CoveragePositive NewsGap Down1.53%CGEMCullinan Therapeutics$8.79+3.2%2.675 of 5 stars3.00$33.50 281.1%5Analyst RevisionPositive News1.53%BPMCBlueprint Medicines$104.64+5.4%1.786 of 5 stars2.76$127.22 21.6%21Earnings ReportAnalyst ForecastNews CoveragePositive News1.52%IBRXImmunityBio$2.54+2.0%1.6149 of 5 stars3.00$12.19 379.8%5Upcoming EarningsGap Up1.52%LYELLyell Immunopharma$0.46-1.9%3.4095 of 5 stars1.50$1.00 116.8%2Upcoming EarningsNews Coverage1.50%PGENPrecigen$1.57+1.3%3.7064 of 5 stars3.00$7.00 345.9%4News CoveragePositive News1.49%IMTXImmatics$5.23+4.4%1.9496 of 5 stars3.20$16.67 218.7%5News CoveragePositive News1.49%LEGNLegend Biotech$33.17-2.3%2.5381 of 5 stars2.92$78.82 137.6%12Positive News1.47%KYMRKymera Therapeutics$35.28+2.1%2.0399 of 5 stars2.87$56.36 59.7%15News CoveragePositive News1.46%MRUSMerus$44.19-2.8%3.2982 of 5 stars3.13$85.31 93.0%16Upcoming EarningsShort Interest ↓Analyst RevisionNews Coverage1.46%RLAYRelay Therapeutics$3.25-1.2%2.0199 of 5 stars2.82$18.36 465.0%11Upcoming EarningsNews Coverage1.46%RCUSArcus Biosciences$9.12+5.8%2.343 of 5 stars3.00$28.38 211.1%10Upcoming EarningsNews CoveragePositive News1.45%VORVor Biopharma$0.66+0.1%2.5808 of 5 stars3.00$8.86 1,239.2%7News CoverageGap Up1.45%CMPXCompass Therapeutics$1.89+3.8%3.4097 of 5 stars3.11$13.38 607.7%9Short Interest ↑Analyst Revision1.44%KURAKura Oncology$6.47-0.3%4.1489 of 5 stars2.92$23.89 269.2%13Earnings ReportAnalyst ForecastNews CoveragePositive News1.44%INBXInhibrx$12.15-1.4%2.3812 of 5 stars2.001Short Interest ↓News CoveragePositive News1.44%ACLXArcellx$65.55+0.0%1.846 of 5 stars3.14$110.67 68.8%14Upcoming EarningsNews CoveragePositive News1.43%REGNRegeneron Pharmaceuticals$605.61+2.6%4.8427 of 5 stars2.88$892.60 47.4%26Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionHigh Trading Volume1.43%YMABY-mAbs Therapeutics$4.41+7.3%3.8231 of 5 stars2.82$17.40 294.6%11Upcoming EarningsShort Interest ↓News Coverage1.43%BCYCBicycle Therapeutics$9.30+2.4%3.5924 of 5 stars2.78$26.00 179.6%9Earnings ReportAnalyst ForecastShort Interest ↓News Coverage1.43%ALLOAllogene Therapeutics$1.70+0.6%3.3559 of 5 stars2.90$9.29 446.4%10Positive News1.41%DAWNDay One Biopharmaceuticals$7.93+4.1%2.579 of 5 stars3.13$32.29 307.1%8Upcoming EarningsNews Coverage1.40%IOVAIovance Biotherapeutics$3.50+5.1%4.5879 of 5 stars2.89$18.22 420.6%9Upcoming EarningsPositive News1.39%ELVNEnliven Therapeutics$20.51+3.3%2.3164 of 5 stars3.25$40.33 96.7%4News Coverage1.38%XNCRXencor$11.26+3.7%3.2695 of 5 stars3.13$32.86 191.8%8Upcoming EarningsAnalyst Forecast1.37%MRKMerck & Co., Inc.$83.14-0.1%5 of 5 stars2.59$111.13 33.7%22Insider TradeAnalyst RevisionPositive News1.37%NRIXNurix Therapeutics$11.27+1.0%1.9794 of 5 stars2.84$30.44 170.1%19Analyst ForecastNews Coverage This page (NASDAQ:CNCR) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNCR Stock Free CNCR Stock Alerts